Berenberg Reiterates Buy on Recursion Pharmaceuticals, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Berenberg analyst Gal Munda has reiterated a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a price target of $33.
July 12, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Berenberg analyst has reiterated a 'Buy' rating on Recursion Pharmaceuticals and maintained a price target of $33.
The reiteration of a 'Buy' rating by Berenberg analyst Gal Munda indicates a positive outlook for Recursion Pharmaceuticals. The maintained price target of $33 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100